Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States.
CONCLUSIONS: Patients incurred significantly lower rates of HE-related and all-cause hospitalizations during rifaximin versus lactulose episodes, resulting in lower facility and professional costs. Cost savings may be possible if rifaximin adherence is improved in HE patients.
LIMITATIONS: The study is subject to limitations common to claims-based analyses.
PMID: 33464935 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Databases & Libraries | Economics | Health Management | Healthcare Costs | Insurance | Study | USA Health | Xifaxan